Results 51 to 60 of about 21,951 (195)

Plasma Elastase Screening in Hematological Disease Reveals Its Potential as a Diagnostic and Prognostic Biomarker in Hematological Malignancies

open access: yesInternational Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction Neutrophil‐extracellular traps are net‐like material released by triggered neutrophils and composed of decondensed chromatin linked to nuclear proteins. Elastase, one of the fourth most represented neutrophil‐specific serine proteases stored in azurophil granules of naïve neutrophils, exerts various actions, including degradation ...
Pasqualina Scala   +14 more
wiley   +1 more source

Down syndrome with microgranular variant of acute promyelocytic leukemia in a child: a case report

open access: yesJournal of Medical Case Reports, 2007
Background Acute promyelocytic leukemia (APL) accounts for less than 10% of pediatric AML. Cases of APL in Down syndrome (DS) have been described in the literature rarely and it is rarer still to find the microgranular variant (M3v) of APL in trisomy 21 ...
Jain Deepali   +2 more
doaj   +1 more source

Assessment of the Performance of Siemens Scopio Digital Morphology on Bone Marrow Aspirates in Onco‐Hematology

open access: yesInternational Journal of Laboratory Hematology, EarlyView.
ABSTRACT Objectives Digital morphology (DM) systems assisted by artificial intelligence are increasingly being introduced into hematology laboratories; however, data on their performance in routine clinical practice for bone marrow aspirates (BMA) remain limited.
Gina Zini   +6 more
wiley   +1 more source

Management of Non‐Plaque‐Induced Gingival Conditions: A Systematic Review—Part 2: Inflammatory and Immune Conditions; Neoplasms; and Gingival Pigmentation

open access: yesJournal of Clinical Periodontology, EarlyView.
ABSTRACT Aims This systematic review assesses current evidence on the management of non‐plaque (dental biofilm)‐induced gingival diseases and conditions (NPIGDs), including (i) inflammatory and immune conditions, (ii) neoplasms and (iii) gingival pigmentations.
Maria Clotilde Carra   +5 more
wiley   +1 more source

Treatment of Acute Promyelocytic Leukemia

open access: yesHematology, 2006
AbstractCure of acute promyelocytic leukemia (APL) is now a possibility for most patients through the use of state-of-the-art treatments, which include simultaneous administration of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy for induction and consolidation, as well as ATRA-based maintenance. Risk-adapted strategies to modulate
openaire   +3 more sources

Survival and treatment response in adults with acute promyelocytic leukemia treated with a modified International Consortium on Acute Promyelocytic Leukemia protocol

open access: yesRevista Brasileira de Hematologia e Hemoterapia
Acute promyelocytic leukemia has good prognosis in view of the high complete remission and survival rates achieved with therapies containing all-trans retinoic acid or arsenic trioxide.
Erick Crespo-Solis   +6 more
doaj   +1 more source

Oral Mucositis in Oncopediatric Patients: MTX and MMP‐1, MMP‐8, MMP‐13 Gene Polymorphisms

open access: yesOral Diseases, EarlyView.
ABSTRACT Background This study investigates the association between single‐nucleotide polymorphisms (SNPs) in the MMP‐1, MMP‐8, and MMP‐13 genes and the risk of oral mucositis development in paediatric patients with leukaemia and lymphoma who are undergoing methotrexate (MTX) treatment.
Nicole Januário Ribeiro   +6 more
wiley   +1 more source

Herpes Simplex Virus Hepatitis: An Overlooked Cause of Acute Liver Failure Across a Broad Spectrum of Immunocompromise

open access: yesLiver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background and Aims Herpes simplex virus (HSV) infection is common worldwide, but hepatic involvement is rare. HSV hepatitis is an uncommon yet frequently catastrophic cause of acute hepatitis and acute liver failure (ALF), accounting for < 1% of ALF cases while carrying very high mortality when diagnosis and antiviral therapy are delayed ...
Mario U. Mondelli   +5 more
wiley   +1 more source

CPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose

open access: yesPediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Background/Objectives Outcomes for pediatric relapsed/refractory (R/R) acute myeloid leukemia (AML) remain dismal. CPX‐351, a liposomal formulation of cytarabine and daunorubicin, may have less off‐target toxicities than traditional chemotherapies and has shown improved outcomes for adults with newly diagnosed therapy‐related AML.
Jonathan D. Bender   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy